Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients

e20056 Background: This study characterizes biomarker testing over time in Non-Small Cell Lung Cancer (NSCLC) patients treated within a clinical setting. There have been tremendous advances in treatments for NSCLC that target specific biomarkers such as epithelial growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and the Programmed cell death-ligand 1 (PD-L1) pathway. As we consider using oncology EMR records for future studies, it is critical to understand the extent to which biomarker testing is conducted in routine care, the extent to which testing has increased, and the types of patients for which it is done. Methods: This is a retrospective observational analysis derived from the COTA Oncology EHR database from January 1, 2015 through December 31, 2017. The data sets generated for the study included all relevant, retrospective patient-level, de-identified data available for patients with lung cancer, including EGFR, ALK, and PD-L1 testing regardless of age, gender, and stage at diagnosis. We examined characteristics associated with each type of test received as well as by those who had received all 3 biomarker tests, 1-2 of the tests, or no biomarker testing. Analyses were conducted using SAS V. 9.1 and stratified by data source. Results: There were 1,891 patients in the COTA database. Among newly diagnosed NSCLC patients, EGFR testing has been consistently conducted in patients during the study period (76 – 86%), while ALK testing [44% in 2015Q1 to 74% in 2017Q4] and PD-L1 testing [12% in 2015Q1 to 77% in 2017Q4] have steadily increased each quarter. Overall, testing was more likely to be conducted in non-squamous cell lung cancer patients, Stage IV lung cancer, and those without a history of smoking. For EGFR, testing was more prevalent among women and young age groups ( < 64 years vs. 65 and older). Conclusions: Biomarker testing has rapidly increased for ALK and PD-L1, which correlates with the uptake of new targeted therapies. Further research could be conducted to understand clinical outcomes associated with this increase in testing as well as the impact on healthcare resource utilization.

Download Full-text

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)

Lung Cancer ◽

10.1016/j.lungcan.2009.06.020 ◽

2010 ◽

Vol 68 (2) ◽

pp. 234-239 ◽

Cited By ~ 83

Author(s):

Aminah Jatoi ◽

Howard L. Ritter ◽

Amylou Dueck ◽

Phuong L. Nguyen ◽

Daniel A. Nikcevich ◽

...

Keyword(s):

Lung Cancer ◽

Weight Loss ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Poor Performance ◽

Small Cell ◽

Double Blind Trial ◽

Small Cell Lung ◽

Double Blind ◽

Lung Cancer Patients

Download Full-text

Decreased energy and phosphorylation status in the liver of lung cancer patients with weight loss

Journal of Hepatology ◽

10.1016/s0168-8278(00)80092-6 ◽

2000 ◽

Vol 32 (6) ◽

pp. 887-892 ◽

Cited By ~ 16

Author(s):

Susanne Leij-Halfwerk ◽

Pieter C Dagnelie ◽

Peter Kappert ◽

Matthijs Oudkerk ◽

Paul E Sijens

Keyword(s):

Lung Cancer ◽

Weight Loss ◽

Cancer Patients ◽

Lung Cancer Patients

Download Full-text

Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study

Frontiers in Oncology ◽

10.3389/fonc.2021.685605 ◽

2021 ◽

Vol 11 ◽

Author(s):

Lotte Van Der Weijst ◽

Veerle Surmont ◽

Wim Schrauwen ◽

Yolande Lievens

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Visual Memory ◽

Patient Reported Outcomes ◽

Post Treatment ◽

Lung Cancer Patients ◽

Systemic Treatments ◽

Patient Reported ◽

The Impact ◽

Over Time

IntroductionThis report investigates the impact of systemic treatments (chemotherapy or immunotherapy) with(out) loco-regional radiotherapy, on HRQoL, toxicity and neurocognitive functioning (NCF) in locally advanced and metastatic non-small cell lung cancer patients enrolled in the PRO-Long study.Materials and MethodsData on patient-reported HRQoL and fourteen toxicities was collected, while NCF was tested, up to one-year post-treatment. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30. Lung cancer, treatment and neuro-psychological related toxicities were scored with the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. NCF was evaluated with six neurocognitive tests. Mixed model analyses were conducted to determine statistical significance (p = .01). Meaningful clinical important differences (MCIDs) were applied for changes in HRQoL and NCF data, while toxicities were compared to baseline values.ResultsIn total, 50 patients were enrolled. Overall HRQoL (p = .357) nor its domains (physical, p = .643; role, p = .069; emotional, p = .254; cognitive, p = 494; social, p = .735) changed significantly over time. Meaningful improvements in overall HRQoL were seen in 22, 38 and 39% and deteriorations in 22, 5 and 28% of patients at 2–3, 6 and 12 months respectively post-treatment. Overall toxicity (p = .007), lack of appetite (p = .001), nausea (p = .004) and dysphagia (p = .000) significantly decreased over time. Treatment caused acute toxicity, such as dyspnoea (45%) and memory problems (42%), but also alleviated pre-existing symptoms, including lack of appetite (32%), anxiety (29%) and depression (28%) at 2/3 months. The NCF domains of visual memory (p = .000) and cognitive processing speed (p = .000) showed significant improvements over time. In terms of MCIDs, at 2–3 months (18%) and 6 months (15%), verbal memory was particularly impacted; at 12 months, visual memory (18%) and executive function (18%) deteriorated primarily.ConclusionThe results suggest that therapy has no significant negative impact on overall HRQoL, its domains, and NCF. About one-third of patients reported a meaningful improved HRQoL at 1 year post-treatment. Treatment caused toxicity, but also alleviated pre-existing symptoms.

Download Full-text